Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore, he highlights the strategic importance of Poland in the region as the company’s footprint continues to grow and highlights the possibilities in the future for local acquisitions, as well as the business approach that has triggered excellent results for the company in neighbouring markets.
What have been the key milestones for the affiliate since you took over the country manager role in 2014?
"We have built our position here step by step, going from being Mr. Nobody in Poland to having a strong presence in gastroenterology, oncology and now, urology."
